Using the gene editing technology CRISPR, scientists have shed light on a rare, sometimes fatal syndrome that causes children to gradually lose the ability to manufacture vital blood cells. The research suggests new lines of investigation into how to treat this condition — dyskeratosis congenita — which is characterized by shortened telomeres. Short telomeres lead to progressive DNA damage that accumulates over time.